Filip A.
- Country
- Belgium
- Department
- Urology
Research Overview
- Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
- Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
- Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials
Data & Insights
Has run more than one trial at 17 of 117 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating bladder cancer, with particular emphasis on early-stage disease management and novel therapeutic approaches for non-muscle invasive bladder cancer.
- Intravesical therapy optimization
- Combined immunotherapy approaches
- BCG treatment protocols
This research area explores innovative treatment combinations to improve patient outcomes in early-stage bladder cancer.
Prostate Cancer Management
The investigator focuses on comprehensive treatment strategies for prostate cancer, including long-term management approaches and therapeutic monitoring.
- Advanced therapeutic interventions
- Long-term treatment outcomes
- Clinical benefit assessment
Their work encompasses continuous evaluation of treatment efficacy and safety in prostate cancer patients.
Metastatic Disease Treatment
The investigator develops targeted approaches for oligorecurrent hormone-sensitive prostate cancer, focusing on precision treatment strategies for limited metastatic disease.
- Metastasis-directed therapy
- Hormone therapy optimization
- Treatment resistance management
This research explores combination approaches for treating metastatic prostate cancer with limited spread.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.